Search - tctmd.com

Displaying 1 - 20 of 23

Sort: Relevancy | Date

Presentation ACC 2023

Complete Revascularization Strategies in Patients Presenting With Acute Coronary Syndrome and Multivessel Coronary Disease

Presenter: Roberto Diletti

March 05, 2023

Presentation ACC 2022

The Clinical Effect Of Arrhythmia Monitoring After Myocardial Infarction

Presenter: Christian Jons

April 04, 2022

Presentation ACC 2021

Randomized trial of high sensitivity Troponin T in the Emergency Department

Presenter: Derek Chew

May 18, 2021

Presentation ACC 2020

Ticagrelor With or Without Aspirin in Acute Coronary Syndrome After PCI: Randomized Evaluation Of Ticagrelor Monotherapy After 3- month Dual-antiplatelet Therapy In Acute Coronary Syndrome The TICO trial

Presenter: Yangsoo Jang

March 30, 2020

Presentation ACC 2020

Mental Stress-Induced Myocardial Ischemia as a Marker for Adverse Cardiovascular Events After MI

Presenter: Zakaria Almuwaqqat

March 30, 2020

Presentation ACC 2019

The SAfety and Efficacy of Femoral Access vs RadIal Access in STEMI: The SAFARI-STEMI Trial

Presenter: Michel R Le May

March 19, 2019

Presentation ACC 2019

Apixaban vs VKA and Aspirin vs Placebo in Patients with Atrial Fibrillation and ACS/PCI: The AUGUSTUS Trial

Presenter: Renato Lopes

March 18, 2019

Presentation ACC 2019

Initiation of Angiotensin-Neprilysin Inhibition after Acute Decompensated Heart Failure: Results of the Open-Label Extension of the PIONEER-HF Trial

Presenter: Adam D. DeVore

March 17, 2019

Presentation ACC 2018

6-Month versus 12-Month or Longer Dual Antiplatelet Therapy After Percutaneous Coronary Intervention in Patients with Acute Coronary Syndrome (SMART-DATE)

Presenter: Hyeon-Cheol Gwon

March 12, 2018

Presentation ACC 2018

A Pragmatic Randomized Trial of CYP2C19 Genotyping Implementation Following Percutaneous Coronary Intervention (PCI)

Presenter: Sony Tuteja

March 12, 2018

Presentation ACC 2018

ARTEMIS: Affordability and Real-world Antiplatelet Treatment Effectiveness After Myocardial Infarction Study

Presenter: Tracy Wang

March 12, 2018

Presentation ACC 2018

Uptake and Utilization of Drug-Eluting Bioresorbable Vascular Scaffolds: A CathPCI Registry Study

Presenter: Ajay J. Kirtane

March 11, 2018

Presentation ACC 2018

Hospital Readmission Following Perioperative Myocardial Infarction Associated with Non-Cardiac Surgery

Presenter: Nathaniel R. Smilowitz

March 11, 2018

Presentation ACC 2017

A Multicenter Randomized Trial Evaluating Clinically Significant Bleeding with Low-Dose Rivaroxaban vs Aspirin, in Addition to P2Y12 inhibition, in ACS

Presenter: Magnus Ohman

March 27, 2017

Presentation ACC 2017

iFR vs FFR-guided Coronary Intervention – iFR-SWEDEHEART

Presenter: Matthias Götberg

March 20, 2017

Presentation ACC 2017

Randomised Trial of FFR-guided Complete Revascularization versus Infarct Artery only Treatment in Multivessel STEMI Patients

Presenter: Pieter Smits

March 20, 2017

Presentation ACC 2017

iFR vs FFR for Guiding Coronary Revascularization – DEFINE-FLAIR

Presenter: Justin E Davies

March 19, 2017

Presentation ACC 2017

Everolimus-eluting Bioresorbable Vascular Scaffolds in Patients with Coronary Artery Disease: ABSORB III Trial 2-Year Results

Presenter: Stephen G. Ellis

March 19, 2017

Presentation ACC 2017

The RAD-MATRIX Study

Presenter: Alessandro Sciahbasi

March 19, 2017

Presentation ACC 2015

The Third DANish Study of Optimal Acute Treatment of Patients with ST-segment Elevation Myocardial Infarction

Presenter: Thomas Engstrom

March 16, 2015

Advertisement

Complete Revascularization Strategies in Patients Presenting With Acute Coronary Syndrome and Multivessel Coronary Disease

The Clinical Effect Of Arrhythmia Monitoring After Myocardial Infarction

Randomized trial of high sensitivity Troponin T in the Emergency Department

Ticagrelor With or Without Aspirin in Acute Coronary Syndrome After PCI: Randomized Evaluation Of Ticagrelor Monotherapy After 3- month Dual-antiplatelet Therapy In Acute Coronary Syndrome The TICO trial

Mental Stress-Induced Myocardial Ischemia as a Marker for Adverse Cardiovascular Events After MI

The SAfety and Efficacy of Femoral Access vs RadIal Access in STEMI: The SAFARI-STEMI Trial

Apixaban vs VKA and Aspirin vs Placebo in Patients with Atrial Fibrillation and ACS/PCI: The AUGUSTUS Trial

Initiation of Angiotensin-Neprilysin Inhibition after Acute Decompensated Heart Failure: Results of the Open-Label Extension of the PIONEER-HF Trial

6-Month versus 12-Month or Longer Dual Antiplatelet Therapy After Percutaneous Coronary Intervention in Patients with Acute Coronary Syndrome (SMART-DATE)

A Pragmatic Randomized Trial of CYP2C19 Genotyping Implementation Following Percutaneous Coronary Intervention (PCI)

ARTEMIS: Affordability and Real-world Antiplatelet Treatment Effectiveness After Myocardial Infarction Study

Uptake and Utilization of Drug-Eluting Bioresorbable Vascular Scaffolds: A CathPCI Registry Study

Hospital Readmission Following Perioperative Myocardial Infarction Associated with Non-Cardiac Surgery

A Multicenter Randomized Trial Evaluating Clinically Significant Bleeding with Low-Dose Rivaroxaban vs Aspirin, in Addition to P2Y12 inhibition, in ACS

iFR vs FFR-guided Coronary Intervention – iFR-SWEDEHEART

Randomised Trial of FFR-guided Complete Revascularization versus Infarct Artery only Treatment in Multivessel STEMI Patients

iFR vs FFR for Guiding Coronary Revascularization – DEFINE-FLAIR

Everolimus-eluting Bioresorbable Vascular Scaffolds in Patients with Coronary Artery Disease: ABSORB III Trial 2-Year Results

The RAD-MATRIX Study

The Third DANish Study of Optimal Acute Treatment of Patients with ST-segment Elevation Myocardial Infarction

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content